EGFR and cancer: The development of compounds such as IMC-C225, an EGFR monoclonal antibody (Baselga, 2001), or ZD1839 (‘Iressa’), an orally active, selective EGFR tyrosine kinase inhibitor (Ciardiello and Tortora, 2001), is representative of this new therapeutic strategy for the treatment of cancer.